Literature DB >> 16902727

Can long-term corticosteriods lead to blindness? A case series of central serous chorioretinopathy induced by corticosteroids.

Jing-Liang Loo1, Shu-Yen Lee, Chong-Lye Ang.   

Abstract

INTRODUCTION: Long-term, high-dose corticosteroid therapy is well-known to cause systemic and ocular complications. A lesser known complication is chronic central serous chorioretinopathy (CSCR). Although idiopathic central serous chorioretinopathy (CSCR) is known to be mild with spontaneous recovery and minimal effects on the final visual acuity, chronic CSCR as a complication of long- term steroid therapy behaves differently, and may cause irreversible visual impairment. CLINICAL PICTURE: Three cases of chronic, recurrent CSCR were precipitated by longterm corticosteroids prescribed for post-renal transplant immunosuppressive therapy, postpituitary surgery and pemphigus vulgaris. TREATMENT AND OUTCOME: Two cases resolved with tapering of corticosteroids while one case was treated by focal laser photocoagulation. Two eyes had severe impairment of vision as a result of subretinal scar formation while the other 4 eyes had mild reduction of visual acuity from retinal epithelium pigment atrophy.
CONCLUSION: Long-term corticosteroid therapy can be complicated by severe, chronic and recurrent CSCR and occasionally peripheral exudative retinal detachment. This may result in subretinal fibrosis and permanent loss of vision.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16902727

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  19 in total

Review 1.  Ocular toxicity from systemically administered xenobiotics.

Authors:  Mitan R Gokulgandhi; Aswani Dutt Vadlapudi; Ashim K Mitra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-07-18       Impact factor: 4.481

2.  Long-Term Outcome of Half-Dose Verteporfin Photodynamic Therapy for the Treatment of Central Serous Chorioretinopathy (An American Ophthalmological Society Thesis).

Authors:  Timothy Y Y Lai; Raymond L M Wong; Wai-Man Chan
Journal:  Trans Am Ophthalmol Soc       Date:  2015

3.  [Spectral domain OCT in central serous chorioretinopathy: description of retinal changes].

Authors:  V Valet; C P Lohmann; M Maier
Journal:  Ophthalmologe       Date:  2012-09       Impact factor: 1.059

Review 4.  Intranasal Corticosteroids and Central Serous Chorioretinopathy: A Report and Review of the Literature.

Authors:  Austin S Nakatsuka; Hossein Nazari Khanamiri; Quy N Lam; Jaafar El-Annan
Journal:  Hawaii J Med Public Health       Date:  2019-05

5.  Photodynamic therapy with verteporfin for chronic central serous choroidoretinopathy and idiopathic choroidal neovascularization-first report from the sultanate of oman.

Authors:  Upender Krishen Wali; Nadia Al-Kharousi; Harith Hamood
Journal:  Oman Med J       Date:  2008-10

6.  Choroidal changes in eyes treated with high-dose systemic corticosteroids for optic neuritis.

Authors:  Jun Hyuk Lee; Ji Young Lee; Ho Ra; Nam Yeo Kang; Jiwon Baek
Journal:  Int J Ophthalmol       Date:  2020-09-18       Impact factor: 1.779

7.  Severe visual loss secondary to central serous chorioretinopathy following prolonged immune suppression with oral prednisolone.

Authors:  A Harikrishnan; K Anderson; S Patra
Journal:  JRSM Short Rep       Date:  2010-09-15

8.  Macular atrophy in birdshot retinochoroidopathy: an optical coherence tomography and multifocal electroretinography analysis.

Authors:  David G Birch; Patrick D Williams; David Callanan; Robert Wang; Kirsten G Locke; Donald C Hood
Journal:  Retina       Date:  2010-06       Impact factor: 4.256

9.  Comparison of the Clinical Manifestations between Acute Vogt-Koyanagi-Harada Disease and Acute Bilateral Central Serous Chorioretinopathy.

Authors:  Woo Beom Shin; Min Kyo Kim; Christopher Seungkyu Lee; Sung Chul Lee; Hyesun Kim
Journal:  Korean J Ophthalmol       Date:  2015-11-25

10.  Relationship between mean platelet volume and central serous chorioretinopathy.

Authors:  Ayhan Dursun; Mustafa Ilker Toker; Ayşe Vural Ozec; Erman Bozali; Kadir Kirboga; Feyza Gulac Dursun; Haydar Erdogan; Aysen Topalkara; Mustafa Kemal Arici
Journal:  Int Ophthalmol       Date:  2016-04-25       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.